[go: up one dir, main page]

MXPA06014768A - Analogos de epitopes. - Google Patents

Analogos de epitopes.

Info

Publication number
MXPA06014768A
MXPA06014768A MXPA06014768A MXPA06014768A MXPA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A
Authority
MX
Mexico
Prior art keywords
analogs
residues
mhc
epitope analogs
norvaline
Prior art date
Application number
MXPA06014768A
Other languages
English (en)
Inventor
David C Diamond
Liping Liu
Adrian Bot
Zhidong Xie
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MXPA06014768A publication Critical patent/MXPA06014768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Algunas modalidades se refiere a analogos de peptidos que corresponden a epitopes de celulas T de MHC restringido clase I y a los metodos para su generacion. Estos analogos pueden contener sustituciones de aminoacidos en residuos que interactuan directamente con las moleculas MHC, y pueden conferir propiedades inmunologicas mejoradas, modificadas o utiles. Adicionalmente, se describen clases de analogos, en los cuales las diversas sustituciones comprenden los residuos no estandar de norleucina y/o norvalina.
MXPA06014768A 2004-06-17 2005-06-17 Analogos de epitopes. MXPA06014768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58096204P 2004-06-17 2004-06-17
US58100104P 2004-06-17 2004-06-17
PCT/US2005/021609 WO2006009920A2 (en) 2004-06-17 2005-06-17 Epitope analogs

Publications (1)

Publication Number Publication Date
MXPA06014768A true MXPA06014768A (es) 2007-06-22

Family

ID=35198081

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06014768A MXPA06014768A (es) 2004-06-17 2005-06-17 Analogos de epitopes.

Country Status (10)

Country Link
US (5) US20060057673A1 (es)
EP (2) EP1765858B1 (es)
JP (2) JP5166025B2 (es)
KR (2) KR20070056042A (es)
AU (1) AU2005265182B2 (es)
CA (1) CA2571168A1 (es)
IL (2) IL180101A (es)
MX (1) MXPA06014768A (es)
SG (1) SG153827A1 (es)
WO (1) WO2006009920A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP1765858B1 (en) * 2004-06-17 2012-11-21 Mannkind Corporation Epitope analogs
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101146550B (zh) * 2004-12-29 2013-04-17 曼康公司 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
AU2005321940B2 (en) 2004-12-29 2012-04-19 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
NZ590125A (en) 2005-06-17 2012-07-27 Mannkind Corp Peptide MHC I analogue comprising the sequence EAAGIGILTIV and use of peptide to induce or regulate a T-cell response
EP2385060A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
MX2007015950A (es) * 2005-06-17 2008-04-04 Mannkind Corp Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma.
US8396671B2 (en) * 2006-02-16 2013-03-12 Microsoft Corporation Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
US8706421B2 (en) * 2006-02-16 2014-04-22 Microsoft Corporation Shift-invariant predictions
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
US20080014211A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
PL2476436T3 (pl) 2006-08-11 2018-05-30 Life Sciences Research Partners Vzw Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
US8121797B2 (en) * 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
AU2008216669B2 (en) * 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
WO2008118017A2 (en) 2007-03-26 2008-10-02 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
MX2009012635A (es) * 2007-05-23 2012-09-13 Mannkind Corp Vectores multicistronicos y metodos para su diseño.
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
JP2013508415A (ja) * 2009-10-23 2013-03-07 マンカインド コーポレイション 癌の免疫療法、および治療の方法
CA2781248A1 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
BR112012022641A2 (pt) 2010-03-11 2017-02-14 Oncotherapy Science Inc peptídeos hjurp e vacinas que incluem os mesmos
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
EP2643345B1 (en) 2010-11-25 2021-02-24 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
WO2012076059A1 (en) * 2010-12-09 2012-06-14 Stichting Het Nederlands Kanker Instituut Immune restricted peptides with increased efficacy
WO2012088414A1 (en) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
AU2016342380B2 (en) 2015-10-23 2022-04-07 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020051566A1 (en) * 2018-09-07 2020-03-12 Immunotope, Inc. Vaccines with enhanced immune response and methods for their preparation
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4598568A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DK0668777T3 (da) 1992-11-05 2007-02-19 Sloan Kettering Inst Cancer Prostataspecifikt membran-antigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
ES2438735T3 (es) 1997-07-10 2014-01-20 Mannkind Corporation Inmunización intralinfática para inducir respuestas de CTL efectores prolongadas
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
ATE440960T1 (de) 1999-02-05 2009-09-15 Univ Melbourne T-helferzellen-epitope
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6605711B1 (en) * 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
EP1230261B1 (en) * 1999-11-15 2008-06-25 Ludwig Institute For Cancer Research Ny-eso-1 nonapeptide derivatives, and uses thereof
DE60043158D1 (de) * 1999-11-18 2009-11-26 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
JP2003524016A (ja) 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
IL152116A0 (en) * 2000-04-05 2003-05-29 Vi Technologies Inc Prion-binding ligands and methods of using same
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
JP2005528338A (ja) * 2002-01-29 2005-09-22 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 「黒色腫阻害活性物質」（ｍｉａ）を阻害する方法
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003230603A1 (en) 2002-03-08 2003-09-22 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
JP2006515744A (ja) * 2002-09-17 2006-06-08 アンテイジエン・エクスプレス・インコーポレーテツド Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン
EP2356999A1 (en) 2003-06-17 2011-08-17 Mannkind Corporation Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
ATE546153T1 (de) * 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
EP1765858B1 (en) * 2004-06-17 2012-11-21 Mannkind Corporation Epitope analogs
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101146550B (zh) * 2004-12-29 2013-04-17 曼康公司 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
AU2005321940B2 (en) * 2004-12-29 2012-04-19 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Also Published As

Publication number Publication date
AU2005265182A1 (en) 2006-01-26
IL180101A (en) 2014-02-27
US8202841B2 (en) 2012-06-19
JP2008283979A (ja) 2008-11-27
US8354380B2 (en) 2013-01-15
US20110301327A1 (en) 2011-12-08
EP2332971A1 (en) 2011-06-15
IL209859A0 (en) 2011-02-28
IL180101A0 (en) 2007-05-15
US20060063913A1 (en) 2006-03-23
US20060094661A1 (en) 2006-05-04
WO2006009920A2 (en) 2006-01-26
JP2008510453A (ja) 2008-04-10
JP5166025B2 (ja) 2013-03-21
EP2332971B1 (en) 2016-02-17
AU2005265182B2 (en) 2012-06-21
WO2006009920A3 (en) 2006-06-15
EP1765858B1 (en) 2012-11-21
US20060057673A1 (en) 2006-03-16
SG153827A1 (en) 2009-07-29
KR20070056042A (ko) 2007-05-31
KR20100092031A (ko) 2010-08-19
US20130195901A1 (en) 2013-08-01
EP1765858A2 (en) 2007-03-28
CA2571168A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
SG153827A1 (en) Epitope analogs
WO2006138562A3 (en) Epitope analogues
IL267186A (en) Epitopes of regulated T cells, preparations and uses
MX338940B (es) Identificacion de epitopos ige novedosos.
AR117007A2 (es) Región constante de anticuerpo mutante
PH12020500677A1 (en) Neoantigens and uses thereof
MX382293B (es) Predicción de inmunogenicidad en epítopos de células t.
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
DK1888761T3 (da) Rekombinante N-glycosylerede proteiner fra prokaryote celler
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2009012420A (es) Reovirus mutantes y metodos para elaboracion y uso.
PE20121564A1 (es) Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
WO2010028066A3 (en) Cd133 epitopes
DE60322225D1 (en) T-zellen-epitope in erythropoietin
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
BRPI0508916A (pt) polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
WO2008154493A3 (en) Novel peptides that inhibit the opening of mammalian tight junctions
MX2019002497A (es) Peptido con actividad para cicatrizacion de heridas.
MX2024000941A (es) Péptidos y receptores manipulados de linfocitos t dirigidos a antígenos fanci, rad51 y pbk y métodos de uso.
WO2024123794A3 (en) A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
WO2003089453A3 (en) INHIBITION OF Ii EXPRESSION IN MAMMALIAN CELLS

Legal Events

Date Code Title Description
FG Grant or registration